Option chain shows key data for TFF Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TFF Pharmaceuticals.

TFF Pharmaceuticals (NASDAQ:TFFP) Stock, Option Chain

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATCH

ENVB

ERNA

FFIC

FRES

HAFC

HCWB

HSDT

INCY

NCNC

PRFX

QUBT

SOAR

TFFP

WAVE

ZENV

ZONE

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

oil-prices-5079975

Earnings

Eurozone

Commodities

Intraday Update

AREN

EYEN

RVYL

SPPL

Crude Oil Dips Over 2%; Bloom Energy Shares Spike Higher

retail sales ai

Equities

S&amp;P 500 Down Over 1%; US Retail Sales Top Expectations

TFF Pharmaceuticals Inc

Oppenheimer analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Outperform and raises the price target from $121 to $135.

Price Target

Analyst Ratings

EEFT

Oppenheimer Maintains Outperform on Euronet Worldwide, Raises Price Target to $135

RBC Capital analyst Frank Morgan maintains eHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHTH#NASDAQ">EHTH</a>) with a Sector Perform and lowers the price target from $13 to $11.

EHTH

RBC Capital Maintains Sector Perform on eHealth, Lowers Price Target to $11

Oppenheimer analyst Martin Yang maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $260 to $480.

Oppenheimer Maintains Outperform on AppLovin, Raises Price Target to $480

Oppenheimer analyst Owen Lau maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Outperform and raises the price target from $265 to $358.

COIN

Oppenheimer Maintains Outperform on Coinbase Glb, Raises Price Target to $358

RBC Capital analyst Scott Hanold maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Sector Perform and raises the price target from $35 to $40.

RBC Capital Maintains Sector Perform on Range Resources, Raises Price Target to $40

Oppenheimer analyst Rupesh Parikh reiterates Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and maintains $165 price target.

Reiteration

Oppenheimer Reiterates Outperform on Target, Maintains $165 Price Target

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and the U.S. Department of Justice are set to present closing arguments on Monday in a trial to determine if Google&#8217;s advertising technology<a href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst"> constitutes an illegal monopoly.</a>
The Details: The DOJ alleges Google maintains a monopoly in "open-web display advertising" by dominating all aspects of the marketplace with a funnel of technologies that match online publishers to advertisers as well as controls the ad exchange market, which matches the buy side to the sell side.&nbsp;
"One monopoly is bad enough. But a trifecta of monopolies is what we have here," Justice Department lawyer Julia Tarver Wood said during her opening statement.
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Google says that the DOJ's case is focused on a narrow niche of digital advertising and that the company's market share of 25% has been decreasing as competition has increased in the space.&nbsp;
According to the AP, court documents show that Google argues the government's case "boil(s) down to the persistent complaints of a handful of Google's rivals and several mammoth publishers."
The case is being heard by U.S. District Judge Leonie Brinkema, in Alexandria, Virginia, who is expected to decide the case and issue a written ruling by the end of the year.&nbsp;
What Else: A District of Columbia judge, in a separate case, ruled in August that Google's search engine business does constitute a monopoly. The DOJ presented its proposed remedies last week, which included the requirement for Alphabet to divest Google Chrome, the internet&#8217;s leading browser with over 60% market share globally.
Other <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale#google_vignette">proposals included</a> forcing Google to share search data with competitors, and ending default search agreements, which make Google the automatic search engine on devices and web browsers like Apple&#8217;s Safari.
&#8220;Google&#8217;s unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways,&#8221; the DOJ said in a statement.
The judge is expected to deliver a final decision in that case next summer.&nbsp;
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alphabet shares are up 1.92% at $167.92 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a></li>
</ul>
Image: Shutterstock

Large Cap

Legal

Tech

GOOG

GOOGL

Google, DOJ Present Closing Arguments In AdTech Trial Monday

RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Outperform and lowers the price target from $25 to $16.

CATX

RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $16

WIIM

RNAZ

TransCode Therapeutics shares are trading lower after the company announced a 1-for-33 reverse stock split.

Wells Fargo analyst Roger Read maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $42 to $52.

Wells Fargo Maintains Overweight on EQT, Raises Price Target to $52

Analog Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NYSE">ADI</a>) short percent of float has fallen 21.05% since its last report. The company recently reported that it has 7.43 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Analog Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Analog Devices has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Analog Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Analog Devices's peer group average for short interest as a percentage of float is 4.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Analog Devices's Recent Short Interest

Old National's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NYSE">ONB</a>) short percent of float has risen 7.32% since its last report. The company recently reported that it has 9.46 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Old National Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Old National has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Old National's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Old National's peer group average for short interest as a percentage of float is 3.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Old National's Recent Short Interest

Time's running out. The Biden administration is in a mad dash to finalize billions in CHIPS Act deals before Trump takes office. With $39 billion in funding at stake, there's no room for delays.
The CHIPS Act, signed in 2022, was supposed to bring <a href="https://www.benzinga.com/markets/equities/24/10/41387939/chipmakers-rally-nvidia-smashes-records-on-tsmc-blowout-earnings-gold-hit-all-time-highs-whats-d">chip production</a> home. The goal? Secure supply chains and cut reliance on Taiwan for advanced semiconductors. It's a big deal for U.S. manufacturing. But there's a catch. While 90% of the money is allocated, most of it hasn't been locked down yet. Only two deals, worth $6.6 billion, are fully finalized, <a href="https://www.commerce.gov/news/press-releases/2024/11/biden-harris-administration-announces-chips-incentives-award-tsmc">according to the Commerce Department.</a>
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Commerce Secretary Gina Raimondo promised to allocate every dollar by the end of the year. But progress? It's been slow. And patience is wearing thin. "We are disappointed by how long and how slow the dispensing of funds has been," said Intel CEO Pat Gelsinger, as reported by Bloomberg. He's frustrated. The process has dragged on for over two years.
President Joe Biden's team is trying to speed things up. Last week, they announced<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> a $6.6 billion deal </a>with Taiwan's TSMC. At least $1 billion should roll out before the year ends. But there's still a lot left to sort out. Intel, the biggest potential recipient, is still negotiating terms to unlock its share.
President-elect Donald Trump, meanwhile, isn't a fan of the CHIPS Act. He's been vocal. He thinks tariffs are a better way to push companies to make chips here. On a podcast with Joe Rogan, he called tariffs the smarter move. His team might shift gears when he takes office. But here's the thing: once a CHIPS Act deal is finalized, it's tough to undo. They're legally binding unless companies don't hold up their end of the bargain.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Analysts like Jeff Koch say Trump could slow things down, even if he doesn't scrap the CHIPS Act. "This had the ancillary benefit of pushing the Biden administration to cut through red tape and disburse CHIPS Act funds while still in power," Koch told Business Insider.
There's also pressure from the clock. January is fast approaching. Biden's team knows the window to finalize these agreements is closing. The next administration could stall or rewrite the rules, adding more uncertainty to a complicated process.
And it's not just about securing funding. There are benchmarks. <a href="https://www.benzinga.com/news/earnings/24/10/41654832/intel-likely-to-report-q3-loss-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Companies like Intel </a>need clear terms to access the money. Another layer of bureaucracy is slowing things down. For Biden, it's a race against time to solidify the vision of the CHIPS Act before Trump's team takes over.
The stakes are high. America needs these funds locked in to compete globally. Chips power everything from smartphones to cars, so falling behind isn't an option. All eyes are on whether Biden can pull this off in time. The pressure's on and there's no room for missteps.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Startups

'We Are Disappointed.' Intel CEO Criticizes Delays As Biden Pushes $6.6 Billion To TSMC

Zebra Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NYSE">ZBRA</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 511 thousand shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zebra Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zebra Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zebra Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zebra Technologies's peer group average for short interest as a percentage of float is 6.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ZBRA

Looking Into Zebra Technologies's Recent Short Interest

Diana Shipping shares are trading lower after the company reported worse-than-expected Q3 sales results.

IMUX

Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.

Wells Fargo maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Equal-Weight and raises the price target from $83 to $100.

Wells Fargo Maintains Equal-Weight on Expand Energy, Raises Price Target to $100

Palatin Technologies shares are trading higher after the company announced the completion of enrollment in its Phase 2 Study of PL8177.

Editor's Note: The headline has been corrected to accurately reflect the quoted material.
Elon Musk on Saturday shared a cryptic tweet on X, hinting at a significant turning point in human history.
What Happened: Musk&nbsp;responded to a post on X by Bojan Tunguz, which referred to an unspecified event as &#8220;one of the major inflection&nbsp;points of human history.&#8221; Musk&#8217;s reply was enigmatic, stating, &#8220;I knew if I brought&nbsp;a sink they would have&nbsp;to let that sink in.&nbsp;How could they not?&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I knew if I brought a sink they would have to let that sink in. How could they not? <a href="https://t.co/voEVBMC7Ht">https://t.co/voEVBMC7Ht</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860199022121943545?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Tesla and SpaceX CEO&#8217;s post on X has left his followers intrigued, as they attempt to decipher the meaning behind his cryptic words.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a>
Why It Matters: Musk is known for his cryptic tweets, which often lead to widespread speculation. His recent tweet, which suggests a significant turning point in human history, has sparked a flurry of theories among his followers.
While the exact meaning behind Musk&#8217;s tweet remains unclear, it underscores his reputation as a thought leader in the tech industry, known for pushing boundaries and challenging conventional thinking.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42152586/judge-rejects-sec-bid-to-penalize-musk-over-missed-deposition">Judge Rejects SEC Bid to Penalize Musk Over Missed Deposition</a></li>
</ul>
Photo: Shutterstock

Social Media

'I Knew If I Brought A Sink': What Does Elon Musk's Cryptic Tweet Mean? (CORRECTED)

B of A Securities analyst Omar Dessouky maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $252 to $375.

B of A Securities Maintains Buy on AppLovin, Raises Price Target to $375

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;



Bottom-picking is risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to mitigate those risks.&nbsp;



For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;



This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. 



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a>The growing demand for EVs has spotlighted companies like Microvast Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;



The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;



Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;



In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;



TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.



A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.



Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.



But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div>Formerly known as Knowledgetree Ventures, My Size (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/">MYSZ</a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;



While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;



My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;



Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;



On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the second quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

TFF Pharmaceuticals to wind down operations

TFF Pharmaceuticals ( ($TFFP) ) has provided an announcement. TFF Pharmaceuticals, Inc. is set to dissolve following its board's approval of a liqu...

TFF Pharmaceuticals to Dissolve and Liquidate Assets

16:45 EST TFF Pharmaceuticals (TFFP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

TFF Pharmaceuticals trading resumes

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

CYCN

MVST

MYSZ

Health Care

Press Releases

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

General

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

Comments

TFF Pharmaceuticals

TFF Pharmaceuticals (TFFP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga